Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday. The publicly traded Seattle biotech company hired… Read More
For 30 years, scientists have been trying to unleash the promise of Interleukin-2 (IL-2), a powerful protein that fights cancer but is highly toxic. Researchers at the University of Washington… Read More